Assembly Biosciences, Inc. (ASMB) News
Filter ASMB News Items
ASMB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ASMB News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ASMB News From Around the Web
Below are the latest news stories about ASSEMBLY BIOSCIENCES INC that investors may wish to consider to help them evaluate ASMB as an investment opportunity.
Gilead Buys $20.1 Million of Assembly Biosciences StockGilead Sciences bought nearly 950,000 more shares of antiviral-therapeutics developer Assembly as part of an amended investment and funding pact. |
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity with a mean reduction of 2.9 log IU/mL in plasma HBV DNA over 28 days of treatment – – Enrollment in final cohort of 400 mg ongoing with data anticipated in 1H 2025 – SOUTH SAN FRANCISCO, Calif., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company devel |
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs—Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash runway to mid-2026— —Additional equity investment raises Gilead’s ownership stake in Assembly Bio to 29.9%— –Funding supports pipeline progress, including amendment to accelerate clinical development of Assembly Bio’s novel small molecule hepatitis D virus candidate ABI-6250— SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Assembly B |
Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimatesOne thing we could say about the analysts on Assembly Biosciences, Inc. ( NASDAQ:ASMB ) - they aren't optimistic... |
Assembly Biosciences: Q3 Earnings SnapshotSOUTH SAN FRANCISCO, Calif. AP) — Assembly Biosciences Inc. ASMB) on Thursday reported a loss of $9.6 million in its third quarter. |
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent UpdatesPositive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral dosing First participants dosed in Phase 1b trial evaluating ABI-5366 in individuals with recurrent genital herpes with interim data expected in first half of 2025Phase 1b trial for ABI-4334, a next-generation highly potent capsid assembly modulator candidate, ongoing in participants with chronic HBV |
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?Here is how Adma Biologics (ADMA) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year. |
Assembly Biosciences' Investigational Herpes Treatment Shows Safety In Healthy Participants (UPDATED)Editor’s Note: The title of the story has been updated to reflect the accuracy of the data Assembly Biosciences, Inc. (NASDAQ:ASMB) released interim pharmacokinetic (PK) and safety results from healthy participants in the Phase 1a portion of its ongoing Phase 1a/b study of ABI-5366, an investigational long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidate for recurrent genital herpes. Due to its extended PK profile, ABI-5366 was well-tolerated and showed a favorable safety p |
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366– ABI-5366 was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days – – Half-life of approximately 20 days supports once-weekly or once-monthly oral dosing; both dosing schedules will be explored in the Phase 1b portion of the study – – Screening of participants with recurrent genital herpes is now underway for Phase 1b – SOUTH SAN FRANCISCO, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing |
Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?Here is how Assembly Biosciences (ASMB) and Adma Biologics (ADMA) have performed compared to their sector so far this year. |